Academic literature on the topic 'Vesicular Acetylcholine Transporter'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Vesicular Acetylcholine Transporter.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Journal articles on the topic "Vesicular Acetylcholine Transporter"
1
Duerr, Janet S., Jennifer Gaskin, and James B. Rand. "Identified neurons in C. elegans coexpress vesicular transporters for acetylcholine and monoamines." American Journal of Physiology-Cell Physiology 280, no. 6 (June 1, 2001): C1616—C1622. http://dx.doi.org/10.1152/ajpcell.2001.280.6.c1616.
Full textAbstract:
We have identified four neurons (VC4, VC5, HSNL, HSNR) in Caenorhabditis elegans adult hermaphrodites that express both the vesicular acetylcholine transporter and the vesicular monoamine transporter. All four of these cells are motor neurons that innervate the egg-laying muscles of the vulva. In addition, they all express choline acetyltransferase, the synthetic enzyme for acetylcholine. The distributions of the vesicular acetylcholine transporter and the vesicular monoamine transporter are not identical within the individual cells. In mutants deficient for either of these transporters, there is no apparent compensatory change in the expression of the remaining transporter. This is the first report of neurons that express two different vesicular neurotransmitter transporters in vivo.
2
Koulen, Peter. "Vesicular acetylcholine transporter (VAChT)." NeuroReport 8, no. 13 (September 1997): 2845–47. http://dx.doi.org/10.1097/00001756-199709080-00008.
Full text
3
Bravo, Dawn T., Natalia G. Kolmakova, and Stanley M. Parsons. "Choline is transported by vesicular acetylcholine transporter." Journal of Neurochemistry 91, no. 3 (November 2004): 766–68. http://dx.doi.org/10.1111/j.1471-4159.2004.02746.x.
Full text
4
Ojeda, Ana M., Natalia G. Kolmakova, and Stanley M. Parsons. "Acetylcholine Binding Site in the Vesicular Acetylcholine Transporter†." Biochemistry 43, no. 35 (September 2004): 11163–74. http://dx.doi.org/10.1021/bi049562b.
Full text
5
Efange, S. M. N. "In vivo imaging of the vesicular acetylcholine transporter and the vesicular monoamine transporter." FASEB Journal 14, no. 15 (December 2000): 2401–13. http://dx.doi.org/10.1096/fj.00-0204rev.
Full text
6
Efange, S. M. N., E. M. Garland, J. K. Staley, A. B. Khare, and D. C. Mash. "Vesicular Acetylcholine Transporter Density and Alzheimer’s Disease." Neurobiology of Aging 18, no. 4 (July 1997): 407–13. http://dx.doi.org/10.1016/s0197-4580(97)00038-9.
Full text
7
Cho, Goang-Won, Myung-Hee Kim, Young-Gyu Chai, Michelle L. Gilmor, Alan I. Levey, and Louis B. Hersh. "Phosphorylation of the Rat Vesicular Acetylcholine Transporter." Journal of Biological Chemistry 275, no. 26 (March 22, 2000): 19942–48. http://dx.doi.org/10.1074/jbc.m902174199.
Full text
8
Varoqui, Hélène, and Jeffrey D. Erickson. "Active Transport of Acetylcholine by the Human Vesicular Acetylcholine Transporter." Journal of Biological Chemistry 271, no. 44 (November 1, 1996): 27229–32. http://dx.doi.org/10.1074/jbc.271.44.27229.
Full text
9
Prado, Vania F., Ashbeel Roy, Benjamin Kolisnyk, Robert Gros, and Marco A. M. Prado. "Regulation of cholinergic activity by the vesicular acetylcholine transporter." Biochemical Journal 450, no. 2 (February 15, 2013): 265–74. http://dx.doi.org/10.1042/bj20121662.
Full textAbstract:
Acetylcholine, the first chemical to be identified as a neurotransmitter, is packed in synaptic vesicles by the activity of VAChT (vesicular acetylcholine transporter). A decrease in VAChT expression has been reported in a number of diseases, and this has consequences for the amount of acetylcholine loaded in synaptic vesicles as well as for neurotransmitter release. Several genetically modified mice targeting the VAChT gene have been generated, providing novel models to understand how changes in VAChT affect transmitter release. A surprising finding is that most cholinergic neurons in the brain also can express a second type of vesicular neurotransmitter transporter that allows these neurons to secrete two distinct neurotransmitters. Thus a given neuron can use two neurotransmitters to regulate different physiological functions. In addition, recent data indicate that non-neuronal cells can also express the machinery used to synthesize and release acetylcholine. Some of these cells rely on VAChT to secrete acetylcholine with potential physiological consequences in the periphery. Hence novel functions for the oldest neurotransmitter known are emerging with the potential to provide new targets for the treatment of several pathological conditions.
10
Kitzman, Patrick. "Changes in vesicular glutamate transporter 2, vesicular GABA transporter and vesicular acetylcholine transporter labeling of sacrocaudal motoneurons in the spastic rat." Experimental Neurology 197, no. 2 (February 2006): 407–19. http://dx.doi.org/10.1016/j.expneurol.2005.10.005.
Full textDissertations / Theses on the topic "Vesicular Acetylcholine Transporter"
1
Richards, Dannette Shanon. "CHARACTERIZATION OF EXCITATORY AMINO ACID NEUROTRANSMITTERS AT MOTONEURON SYNAPSES CONTACTING RENSHAW CELLS." Wright State University / OhioLINK, 2009. http://rave.ohiolink.edu/etdc/view?acc_num=wright1260896604.
Full text
2
Quinlivan, Mitchell Owen Jeffrey. "Functions of the Cholinergic System in the Morbidities Associated with Alzheimer’s Disease and the Further Evaluation of Tools for the Molecular Imaging of this System." University of Sydney, 2007. http://hdl.handle.net/2123/1933.
Full textAbstract:
Doctor of Philosophy(PhD)The aims of this project were to contribute to the elucidation of the role of the cholinergic system in attention and memory, two cognitive processes severely compromised in Alzheimer’s disease (AD), and to evaluate and develop tools for the functional molecular imaging of this system with a view to improving knowledge of AD and other neurological disorders. Towards the first aim, the specific anti-cholinergic toxin 192 IgG-saporin (SAP) was administered to female Sprague-Dawley rats via either an intracerebroventricular (icv) or an intracortical route and animals were tested with a vibrissal-stimulation reaction-time task and an object recognition task to evaluate their attentional and mnemonic function, respectively. The second aim was approached in two ways. Firstly, relative neuronal densities from animals with icv lesions were assessed with both ex vivo and in vitro autoradiography with the specific cholinergic radiopharmaceuticals [123I]iodobenzovesamicol (123IBVM) and 125I-A-85380, ligands for the vesicular acetylcholine transporter and the nicotinic acetylcholine receptor, respectively. Secondly, a number of in vivo and in vitro studies were performed on a novel and unique molecular imaging system (TOHR), with which it had been hoped initially to image eventually SAP-lesioned animals, with a view to measuring and ameliorating its performance characteristics and assessing its in-principle suitability for small-animal molecular imaging. The behavioural studies support a critical role for the cholinergic system in normal attentional function. Additionally, in accord with literature evidence, no significant impairment was observed in mnemonic function. It is postulated however that the results observed in the intracortically-lesioned animals support the published hypothesis that cholinergic projections to the perirhinal cortex are critical for object-recognition memory. In autoradiographic studies, SAP-lesioned animals demonstrated reduced uptake of 123IBVM in multiple regions. A reduction of nicotinic receptors was also seen in SAP-lesioned animals, a novel finding supportive of the excellent characteristics of radioiodinated I-A-85380. Examination of the performance characteristics of the TOHR support in principle its utility for targeted small-animal molecular imaging studies.
3
Miranda, Claúdia Jeane Claudino de Pontes. "Avaliação da função e da histopatologia pulmonar em modelo experimental de inflamação pulmonar alérgica crônica: efeitos da redução da função colinérgica em camundongos geneticamente modificados." Universidade de São Paulo, 2012. http://www.teses.usp.br/teses/disponiveis/5/5165/tde-27072012-104906/.
Full textAbstract:
INTRODUÇÃO: A Asma Brônquica é caracterizada por obstrução ao fluxo aéreo, reversível ou não, e processo inflamatório pulmonar, caracterizado principalmente por eosinofilia. A persistência da inflamação pode induzir processo de reparo pulmonar associado à redução progressiva da função pulmonar. A recente descrição do sistema colinérgico anti-inflamatório, um mecanismo neural que suprime a resposta imune inata e controla a inflamação por inibição de citocinas proinflammatórias, e a detecção de alguns de seus componentes em células de vias aéreas sugerem uma importante participação deste sistema na fisiopatologia de doenças pulmonares. O principal mediador deste sistema é a acetilcolina (ACh), que é estocada em vesículas sinápticas pelo transportador vesicular de ACh (VAChT), proteína essencial para sua liberação. OBJETIVOS: Avaliar os efeitos da deficiência colinérgica por redução da VAChT nas alterações pulmonares observadas em modelo experimental de inflamação pulmonar induzida pela exposição crônica a ovoalbumina. METODOLOGIA: A redução colinérgica foi induzida pela modificação genética nos níveis de VAChT. Camundongos machos selvagens e mutantes foram submetidos ao protocolo de sensibilização subcutânea com ovoalbumina ou salina nos dias 0, 7 e 14. Após, foram submetidos a desafios inalatórios com ovalbumina a 1% ou inalações de salina por 20 minutos nos dias 26, 27 e 28. No dia 29, foi realizada a avaliação da mecânica pulmonar, da inflamação no lavado broncoalveolar e no tecido e análise histológica de remodelamento e expressão de MMP-9 e TIMP-1 por imunohistoquímica. Também foi quantificado por ELISA níveis de IL-4, IL-10 e de TNF-a no homogenato pulmonar. A análise estatística considerou um p<0,05 como significativo. RESULTADOS: Animais sensibilizados apresentaram hyperresponsividade brônquica, inflamação e edema peribrônquico e deposição de fibras colágenas e elásticas ao redor das vias aéreas comparado ao grupo salina (p<0,05). Além disso houve aumento de IL-4 no homogenato pulmonar e da expressão de MMP-9 e TIMP-1 nas células inflamatórias. Os animais mutantes, independente de serem ou não sensibilizados, apresentaram aumento de TNF-a no pulmão. Os animais mutantes que foram submetidos ao protocolo de sensibilização mostraram aumento da hiperresponsividade brônquica, do eosinófilos, do edema e da deposição de colágeno comparado aos animais selvagens que também foram sensibilizados com ovoalbumina. Estas alterações podem ser atribuídas ao aumento de IL-4 e de MMP-9/TIMP-1 que foi observado nos animais mutantes e sensibilizada em comparação com o os selvagens sensibilizados. Não houve diferença nos níveis de IL-10 nos grupos experimentais. Conclusão: A deficiência colinérgica piora a hiperresponsividade brônquica, a inflamação eosinofílica e o remodelamento, principalmente por interferir com a citocina pró-inflamatória IL-4 e na proporção de MMP-9 e TIMP-1. Estes dados sugerem que a via colinérgica antiinflamatória está envolvida na fisiopatogenia da asma e necessita ser mais investigadaBACKGROUND: Bronchial asthma is characterized by reversible or not airflow obstruction and pulmonary inflammation, mainly characterized by eosinophilia. The persistence of inflammation can induce lung repair process associated with progressive reduction in lung function. Recent evidence of the cholinergic anti-inflammatory system, a neural mechanism that suppresses the innate immune response and control inflammation by proinflammatory cytokines inhibition, and the detection of some of its components in airway cells suggest an important role of this system in pulmonary physiopathology. The main mediator of this system is acetylcholine (ACh), which is stored in synaptic vesicles by vesicular acetylcholine transporter (VAChT), an essential protein for ACh release. AIMS: To evaluate the effects of cholinergic deficiency by VAChT reduction on pulmonary alterations observed in an experimental model of pulmonary inflammation induced by chronic exposure to ovalbumin. METHODS: The cholinergic deficiency was induced by genetic modification on VAChT levels. Wild-type and mutant male mice were submitted to subcutaneous ovalbumin sensitization or saline protocol on days 0, 7 and 14. After, animals were submitted to inhalation challenge with ovalbumin 1% or saline for 20 minutes on days 26, 27 and 28. On day 29, we evaluated the pulmonary mechanics, inflammation in bronchoalveolar lavage and in airways, histological analysis of airway remodeling and the expression of MMP-9 and TIMP-1 by immunohistochemistry. It was also quantified by the levels of IL-4, IL-10 and TNF-a in lung homogenate. The statistical analysis were performed and a p<0.05 was considered significant. RESULTS: Sensitized animals presented bronchial hyperresponsividade, airway inflammation and edema and collagen and elastic fibers deposition of collagen and elastic fibers around the airways compared to saline group (p <0.05). Furthermore, there was an increase of IL-4 in lung homogenate and the expression of MMP-9 and TIMP-1 in inflammatory cells. The mutant animals, regardless the sensitization, showed an increase in lung content of TNF-a. The mutant and sensitized animals showed an increase in bronchial hyperresponsiveness, in eosinophils, edema and collagen deposition in airways compared to the wild type and sensitized animals. These changes can be attributed to increased IL-4 and MMP-9/TIMP-1 that were observed in mutant and sensitized animals. There was no difference in levels of IL-10 in the experimental groups. Conclusion: The cholinergic deficiency worsens bronchial hyperresponsiveness, eosinophilic inflammation, and airway remodeling mainly by interfering with the pro-inflammatory cytokine IL-4 and in MMP-9/TIMP-1 ratio. These data suggest that anti-inflammatory cholinergic pathway is involved in the asthma pathogenesis deserves further investigation
4
Lee, Na-Ra. "DISCOVERY OF NOVEL PHARMACOTHERAPEUTICS FOR SUBSTANCE USE DISORDERS." UKnowledge, 2019. https://uknowledge.uky.edu/pharmacy_etds/104.
Full textAbstract:
Substance use disorders are serious health concerns in the United States. Furthermore, the National Survey on Drug Use and Health reports a continuous increase in substance use disorders in the United States during the last 10 years. However, there are not many effective pharmacotherapeutics available for substance use disorders. The current dissertation is focused on research aimed at discovering pharmacotherapeutics for substance use disorders. First part of dissertation focused on discovering methamphetamine (METH) use disorder therapeutics targeting specific mechanism of METH action on dopaminergic neurons. The second part of dissertation focused on opioids and cocaine use disorder therapeutics targeting rewarding pathway commonly activated by opioids and cocaine.
With respect to METH, it induces release of dopamine (DA) in neuronal terminals by interacting with the vesicular monoamine transporter-2 (VMAT2) and DA transporter (DAT). VMAT2 inhibitors have been found by our research group to decrease METH-evoked DA release, METH-induced hyperlocomotion, and METH self-administration in rats. However, these VMAT2 inhibitors lacked selectivity and tolerance developed to these pharmacologic effects after repeated administration, thereby limiting their potential as pharmacotherapeutics for METH use disorders. In the current study, analogs from a novel scaffold were found to selectively inhibit VMAT2 and were evaluated using neurochemical and behavioral pharmacological approaches. R- and S-3-(4-methoxyphenyl)-N-(1-phenylpropan-2-yl)propan-1-amine (GZ-11610 and GZ-11608, respectively) exhibited 94- to 3450-fold selectivity for VMAT2 over human-ether-a-go-go (hERG) channel, DAT, serotonin transporter, and nicotinic acetylcholine receptors. GZ-11608 competitively and concentration-dependently inhibited METH-evoked DA release via VMAT2. Also, GZ-11610 (56-300 mg/kg, oral) and GZ-11608 (300 mg/kg, oral; 10-30 mg/kg, s.c.) reduced METH-induced hyperlocomotor activity in METH-sensitized rats. Furthermore, GZ-11608 (1-30 mg/kg, s.c.) inhibited METH self-administration, cue- and METH-induced reinstatement in a dose-dependent manner, and 30 mg/kg (s.c.), 10 mg/kg (s.c.), and 17 mg/kg (s.c.) produced significant effect, respectively. Importantly, the GZ-11608-induced decrease in METH self-administration was not surmounted by increasing the amount of METH available. GZ-11608 did not substitute for METH and did not serve as a reinforcer in rats self-administering METH and drug naïve rats, respectively. Thus, these VMAT2 inhibitors incorporating a new scaffold are novel leads for new pharmacotherapeutics to treat METH use disorders.
Substances with high abuse potential including opioids and cocaine elevate extracellular DA concentration in the nucleus accumbens, and this mechanism has long been considered to underly substance-induced reward. DA in the nucleus accumbens originates from DA neuron cell bodies located in the ventral tegmental area in the midbrain. Interestingly, M5 muscarinic acetylcholine receptors (mAChRs) are proteins that are highly expressed on ventral tegmental area DA neurons. Also, studies investigating M5 mAChRs knockout mice showed reduced responding for cocaine in cocaine self-administration and decreased time spent in cocaine-paired and morphine-paired place preference studies. Pharmacological inhibition of M5 mAChRs function via microinfusing mAChR antagonists exhibiting no selectivity among M1-M5 mAChRs subtypes into the ventral tegmental area where expression of M5 mAChRs are dominant, reduced morphine-induced hyperlocomotion and cocaine seeking behaviors in rats. These studies support therapeutic potential of M5 mAChRs selectivity antagonists in opioids and cocaine use disorders. Thus, in the current study, affinity of a series of pethidine and quinuclidinyl N-phenylcarbamate analogs for M5 mAChRs was evaluated using in vitro and ex vivo neuropharmacological assays. Among the pethidine analogs, compound 6a showed the highest binding affinity at M5 (Ki = 0.38 µM), but also high affinity at M1 and M3 mAChRs (0.67 and 0.37 µM, respectively). Among the quinuclidinyl N-phenylcarbamate analogs, compound 13c exhibited the highest affinity at M5 (Ki = 1.8 nM), but also high affinity at M1, M2, M3 and M4 mAChRs (Ki = 1.6, 13, 2.6, 2.2 nM, respectively). Also, 13c acted as an agonist of mAChRs on oxotremorine-induced DA release from rat striatal slices. In addition, compound 13b was found exhibiting the highest selectivity (17-fold) at M3 over M2 mAChRs, suggesting potential of 13b as a chronic obstructive pulmonary disease therapeutics. Taken together, these novel analogs serve as leads for further discovery of subtype-selective M5 mAChR antagonists that may have potential as therapeutics for substance use disorders, as well as for chronic obstructive pulmonary disease.
5
Franco, Rosana Banzato. "Efeitos da redução da função colinérgica na mecânica e na histopatologia pulmonar em modelo experimental de enfisema." Universidade de São Paulo, 2014. http://www.teses.usp.br/teses/disponiveis/5/5165/tde-27022014-145652/.
Full textAbstract:
Introdução: O enfisema pulmonar é o maior componente da doença pulmonar obstrutiva crônica (DPOC), é caracterizado pelo alargamento, destruição alveolar e inflamação do parênquima e vias aéreas pulmonares. A recente descrição do sistema colinérgico anti-inflamatório, um mecanismo neural que controla a inflamação por inibição de citocinas pró-inflamatórias, sugere uma importante participação deste sistema na fisiopatologia das doenças pulmonares. A acetilcolina (ACh), principal mediador deste sistema, é estocada em vesículas sinápticas pelo transportador vesicular de ACh (VAChT), proteína essencial para sua liberação na fenda sináptica. Objetivos: Avaliar se os efeitos da hipofunção colinérgica, por redução da expressão do VAChT, interferem com as alterações pulmonares em modelo experimental de enfisema pulmonar. Metodologia: Camundongos machos selvagens e mutantes, estes últimos com redução da função colinérgica por modificação genética nos níveis do VAChT, foram submetidos ao protocolo de elastase (PPE instilação nasal) ou salina. No dia 28, foi avaliado a função pulmonar, a inflamação e o remodelamento pulmonar. Por imunohistoquímica, avaliou-se a expressão de macrófago, NF-kB e isoprostano no pulmão. Algumas citocinas pró-inflamatórias foram avaliadas no homogenato pulmonar pelo Bioplex. Resultados: Animais selvagem que receberam elastase tiveram redução de elastância de tecido, aumento da inflamação no LBA e no tecido, aumento de citocinas pró-inflamatórias e IL-10, aumento do remodelamento pulmonar, e da expressão de NF-kB e de isoprostano. A deficiência colinérgica nestes animais submetidos ao mesmo protocolo de elastase amplificou a resposta inflamatória (macrófago e neutrófilo) no pulmão, níveis de MCP-1 e também aumento células positivas para NF-kB e isoprostano na região do eixo broncovascular. Conclusão: A ACh parece ter um papel protetor da inflamação neste modelo de enfisema pulmonar, pelo menos em parte pelo controle do NF-kB e do estresse oxidativo. Estes resultados sugerem ainda que o remodelamento e a função pulmonar no enfisema experimental não dependem totalmente do grau de inflamação pulmonarBanckground: Pulmonary emphysema is a major component of chronic obstructive pulmonary disease (COPD), is characterized by enlargement, alveolar destruction and inflammation of the airways and lung tissue. The recent description of the cholinergic anti-inflammatory, a neural mechanism that controls inflammation by inhibition of proinflammatory cytokines, suggests an important role of this system in the pathophysiology of lung disease. The main mediator of this system is acetylcholine (ACh), which is stored in synaptic vesicles by vesicular acetylcholine transporter (VAChT) protein, which is essential for ACh release into the synaptic cleft. Aim: To evaluate whether the effects of cholinergic hypofunction by reduction on VAChT expression, interferes with pulmonary alterations in an experimental model of pulmonary emphysema. Methods: Male mice wild-type and mutant, the last one with reduced cholinergic function by genetic modification in the levels of VAChT, were submitted to the protocol of elastase (PPE intranasally) or saline. On day 28, pulmonary mechanics, inflammation in bronchoalveolar lavage fluid and tissue remodeling were analyzed. By immunohistochemistry, the expression of macrophage, NF-kB and isoprostane in lung was evaluated. Some proinflammatory cytokines were measured in lung homogenate by Bio Plex. Results: Wild-Type animals that received elastase presented a reduction in tissue elastance, an increase in BALF and tissue inflammation as well as in proinflammatory cytokines, IL-10, pulmonary remodeling, and expression of NF-kB and isoprostane. Cholinergic deficient in these animals submitted to the same elastase-induced emphysema protocol amplified the inflammatory response (macrophage and neutrophils) in the lungs, the levels of MCP-1 and the number of positive cells to NF-kB and isoprostane in bronchovascular axis. Conclusions: The ACh seems to have a protective role inflammation in this experimental model of emphysema, at least in part by controlling NF-kB and oxidative stress. These results further suggest that the remodeling and lung function in experimental emphysema does not depend entirely on the degree of lung inflammation
6
Pinheiro, Nathalia Montouro. "Efeito da redução da função colinérgica na mecânica pulmonar e na histopatologia pulmonar em modelo experimental de inflamação aguda induzida por instilação de LPS em camundongos geneticamente modificados." Universidade de São Paulo, 2016. http://www.teses.usp.br/teses/disponiveis/5/5165/tde-04082016-152420/.
Full textAbstract:
A lesão pulmonar aguda (LPA) é caracterizada por inflamação pulmonar de início súbito com recrutamento de polimorfonucleares e liberação de mediadores próinflamatórios. É uma condição grave que evolui com óbito em aproximadamente 40% dos casos. Diversos estudos que elucidaram a fisiopatologia da LPA, o tratamento ainda é insatisfatório. O sistema colinérgico anti-inflamatório foi descrito no pulmão e está relacionado a um reflexo via nervo vago que inibe a liberação de citocinas inflamatórias por efeitos relacionados a ação da acetilcolina em receptores nicotínicos. Nossa hipótese é de que a redução de VAChT, que está relacionada ao déficit na liberação de ACh, module a resposta inflamatória pulmonar em modelo de LPS. Objetivo: 1. Avaliar se a deficiência de VAChT modula a resposta pulmonar em animais geneticamente modificados; 2. Avaliar se a deficiência colinérgica induzida por redução de VAChT está envolvida na resposta pulmonar ao LPS e elucidar alguns mecanismos envolvidos; 3. Avaliar o potencial terapêutico do PNU, um agonista de alfa7nAChR nas alterações funcionais e histopatológicas em modelo de LPA em animais C57Bl6. Metodologia: Foram utilizados camundongos machos geneticamente modificados mutante (VAChT KDHOM) ou selvagem (WT) e C57BL/6. Inicialmente avaliamos a função pulmonar e a histopatologia pulmonar em animais VAChT KDHOM. Após, animais WT e VAChT KDHOM receberam instilação intranasal de LPS ou salina e a resposta inflamatória foi avaliada de 1,5h até 72 horas após. Ainda, foi avaliado a resposta pulmonar em VAChT KDHOM e WT após a instilação de LPS intraperitoneal. Por fim, animais C57BL/6 instilados com LPS intranasal, receberam tratamento prévio ou após com PNU, agonista do receptor nicotínico alfa7. Resultados: Animais mutante apresentaram maior quantidade de células recuperadas no lavado bronco alveolar (LBA) e aumento de citocinas próinflamatórias, aumento de edema peribrônquico e piora da função pulmonar. Ainda, observamos aumento da expressão de NF-kB e redução de JAK2. A deficiência de VAChT induziu aumento de células inflamatórias em animais que receberam LPS somente em 1.5h após a indução, sendo os valores iguais ao dos animais WT em 24 e 72 horas. Nos animais WT, o estimulo do receptor nicotínico melhora a inflamação, enquanto o estímulo de receptores muscarínicos parece contribuir com a piora da resposta da inflamação pulmonar. Os efeitos do PNU parecem que dependem da via colinérgica intacta, uma vez que esta droga não teve o mesmo efeito em animais mutante. Entretanto, o tratamento com PNU em animais C57BL/6 reduziu a inflamação, a produção de citocinas, a deposição de colágeno no tecido pulmonar e os níveis de MMP-2, MMP-9 e TIMP-1, melhorando a função pulmonar. Estes efeitos parecem estar associados a redução de macrófagos perfil M1, e a inibição de NF-kB. Conclusão: Estes dados claramente demonstram que o sistema colinérgico anti-inflamatório está envolvido no controle da resposta inflamatória pulmonar, seja na manutenção da homeostasia ou ainda nas fases iniciais do desenvolvimento da LPA. Ainda, está claro que o estímulo de receptores nicotínicos tem grande potencial como alvo terapêutico a ser explorado na SDRAAcute lung injury (ALI) is characterized by acute lung inflammation with recruitment of polymorphonuclear and release of proinflammatory mediators. It is a severe condition since leads to death 40% of the cases. Several studies have elucidated the pathophysiology of ALI, however the treatment is still unsatisfactory. The anti-inflammatory cholinergic system was described in the lung and is related to a vagal nerve reflex that inhibits the release of inflammatory cytokines by the action o ACh on nicotinic receptors. Our hypothesis is that the VAChT reduction, which is related to the deficit in the release of ACh, modulates the pulmonary inflammatory response in a model of LPS. Aim: 1. To assess whether VAChT deficiency modulates the pulmonary response in genetically modified animals; 2. Assess whether cholinergic deficiency induced reduction VAChT is involved in pulmonary response to LPS and elucidate some mechanisms involved; 3. To evaluate the therapeutic potential of PNU, an agonist alfa7nAChR, in functional and histological changes in C57BL6 mice with LPA. Methods: Mutant genetically modified male mice (VAChT KDHOM) or wild (WT) and C57BL/6 were used. First, we evaluated lung function and lung histopathology in VAChT KDHOM animals. After, WT animals and VAChT KDHOM received intranasal instillation of LPS or saline and the inflammatory response was assessed 1.5 hours to 72 hours. Moreover, the pulmonary response was evaluated in WT and VAChT KDHOM after instillation of LPS intraperitoneally. Finally, C57BL6 instilled with intranasal LPS received prior or post-treatment with PNU, an alfa7 nicotinic receptor agonist. Results: Mutant animals had higher number of cells recovered in brochoalveolar lavage (BAL) and increased pro-inflammatory cytokines, peribronchial edema and worsening of lung function. Still, there was an increase of NF_kB expression and reduction of JAK2. The VAChT deficiency induced increase in inflammatory cells in animals receiving LPS only 1.5h after the LPS instilation, and the values were similar to WT in 24 and 72 hours. In WT mice, the stimulation of the nicotinic receptor improves inflammation, while the stimulation of muscarinic receptors appears to contribute to the worsening of the pulmonary inflammatory response. The effects of PNU seem to depend on the intact cholinergic pathway, since this drug had no effects on mutant animals. However, treatment with PNU in C57BL6 reduced pulmonar inflammation, cytokine production, collagen deposition in lung tissue and the levels of MMP-2, MMP-9 and TIMP-1, improving pulmonary function. These effects appear to be associated with reduced profile M1 macrophages and the inhibition of NF-kB. Conclusion: These data clearly demonstrate that the anti-inflammatory cholinergic system is involved in the control of lung inflammatory response, both to maintain the lung homeostasis or in the early stages of the development of ALI. Finally, it is clear that the stimulation of nicotinic receptors has great potential as a therapeutic target to be explored in ARDS
7
Kuznetsova, Elena. "β-AMYLOID, CHOLINERGIC TRANSMISSION, AND CEREBROVASCULAR SYSTEM - A DEVELOPMENTAL STUDY IN A TRANSGENIC MOUSE MODEL OF ALZHEIMER’S DISEASE." Doctoral thesis, Universitätsbibliothek Leipzig, 2013. http://nbn-resolving.de/urn:nbn:de:bsz:15-qucosa-112763.
Full textAbstract:
Grundlage der vorgelegten Arbeit sind die bei der Alzheimerschen Erkrankung beobachtbaren pathologischen Merkmale, wie die progressive Akkumulation von β-Amyloid-Plaques, cholinerger Dysfunktion und zerebrovaskuläre Abnormalitäten. Die in englischer Sprache verfasste Dissertation ist eine tierexperimentelle Studie, die versucht, den Zusammenhang von β-Amyloid, cholinerger Neurotransmission und zerebralem Gefäßsystem bei der Alzheimerschen Erkrankung näher zu charakterisieren. An Hirnmaterial aus der transgenen Maus Tg2576, die die schwedische Mutation des humanen Amyloidpräkursorproteins als Transgen trägt und ab dem 10. Lebensmonat durch humane β-Amyloid-Plaqueablagerungen in der Hirnrinde imponiert, wurden im Altersverlauf (4 bis 18 Monate) immunhistochemische Untersuchungen zur morphologischen Integrität der zerebralen Mikrogefäße, der kortikalen cholinergen Nervterminalen und der intrazerebralen cholinergen neurovaskulären Innervation durchgeführt.
Am somatosensorischen Kortex werden beispielhaft die Expression des Glukosetransporters 1 oder Solanum tuberosum Lektin als Kapillarmarker und des vesikulären Acetylcholintransporters als Marker für cholinerge Fasern mittels Immunfluoreszenz und Laser-Scanning Mikroskopie erfasst, einer semiquantitativen Computer-gestützten Bildanalytischen Auswertung unterzogen und mit dem Ausmaß der kortikalen Plaquebeladung korreliert. So konnte gezeigt werden, dass die Dichte der Blutgefäße und cholinergen Fasern im somatosensorischen Kortex von transgenen Tieren mit dem Alter im Vergleich zu nichttransgenen Kontrolltieren abnimmt, was mit einer Reduktion der perivaskulären cholinergen Innervation einhergeht.
Die erhobenen Befunde stützen die von J.C. de la Torre und T. Mussivand schon im Jahre 1993 formulierte „vaskuläre Hypothese“, wonach bei der sporadischen Form der Alzheimerschen Erkrankung alters- und Lebensstil-bedingte Schädigungen des zerebralen Gefäßsystems eine zentrale Rolle bei der Manifestierung der Erkrankung spielen.
8
Santana, Fernanda Paula Roncon. "Efeito da hipofunção colinérgica na mecânica e na histopatologia pulmonar em modelo experimental de inflamação pulmonar induzida por instilação de poluente em camundongos." Universidade de São Paulo, 2014. http://www.teses.usp.br/teses/disponiveis/5/5165/tde-26012015-090146/.
Full textAbstract:
Os motores a diesel são bastante utilizados nos centros urbanos e sua queima é considerada um grande poluidor ambiental e tóxico para a saúde humana. Devido suas características químicas, as partículas de diesel atingem as vias aéreas mais distais, o que pode induzir inflamação pulmonar e piorar doenças como asma brônquica e enfisema pulmonar. Recentemente foi demonstrado por nosso grupo que o sistema colinérgico anti-inflamatório é um importante modulador da inflamação pulmonar. Assim, nosso objetivo no presente estudo foi avaliar se a deficiência colinérgica induzida por alteração genética para redução da expressão da proteína vesicular transportadora de acetilcolina (VAChT) interfere nas alterações funcionais e histopatológicas pulmonares em modelo experimental de instilação repetida de partículas de exaustão de diesel (DEP). Para tanto, camundongos machos geneticamente modificados para redução de VAChT foram utilizados, divididos de acordo com a genotipagem em selvagem (WT) e knock-down para VAChT (KD) e submetidos ao protocolo de exposição de DEP, que consistiu em instilação intranasal de 10uL de DEP na concentração de 3mg/mL por 30 dias (5x por semana). Animais dos grupos controle receberam salina seguindo mesmo protocolo. Foram avaliados: alterações de mecânica do sistema respiratório, resposta inflamatória no lavado broncoalvelar (LBA), imunohistoquimica e Elisa para detecção de citocinas, remodelamento da matriz extracelular pulmonar e presença de muco no epitélio brônquico e nasal. Nossos resultados mostraram que animais selvagens submetidos à DEP apresentaram aumento de macrófagos no LBA e células mononucleares no sangue, da expressão de TNF-alfa, IL-4, IL-6 e IL-13 no tecido pulmonar, de remodelamento de fibras colágenas no tecido e aumento na produção de muco neutro nas vias aéreas quando comparado ao controle exposto à salina. Estas alterações foram associadas a uma piora da função pulmonar. A deficiência colinérgica nos animais que foram submetidos à instilação de DEP induziu um aumento de neutrófilos e linfócitos no LBA e granulócitos no sangue, da expressão de IL-4 e TNF-alfa no pulmão e do conteúdo de fibras elásticas na parede do septo alveolar. Além disso, induziu um aumento de muco ácido no epitélio nasal. Estes dados sugerem que, pelo menos em parte, o sistema colinérgico interfere na inflamação pulmonar induzida por exposição à DEP, uma vez que animais com deficiência colinérgica apresentam piora de alguns parâmetros inflamatórios não observados ou observados em menor escala nos animais selvagensDiesel automotive engines are widely used in urban centers and its exhausts is considered a major environmental and toxic pollutant to human health. Because of their chemical characteristics, diesel particulate reaches more distal airways, which can induce and worsen pulmonary inflammation diseases such as bronchial asthma and pulmonary emphysema. It has recently been demonstrated by our group that the cholinergic anti-inflammatory system is an important modulator of lung inflammation. Thus, the aim of this study was to evaluate whether the cholinergic deficiency induced by reduced expression of the vesicular acetylcholine transporter protein (VAChT) interferes in pulmonary function and histopathological changes in an experimental model of repeated diesel exhaust particles (DEP) instillation. To this end, male mice with reduction in VAChT were used, divided according to genotyping for wild-type (WT) and knock-down for VAChT (KD), and submitted to DEP exposure protocol, which consisted in intranasal instillation of 10 ?L of DEP in a concentration of 3 mg/mL for 30 days (5x per week). Control groups received saline following the same protocol. We evaluated: respiratory mechanics, inflammation in broncoalveolar lavage (BAL), immunohistochemistry and ELISA for cytokine detection, pulmonary extracellular matrix remodeling and bronchial and nasal epithelium mucus. Our results showed that WT animals submitted to DEP protocol showed increased macrophages in BAL and mononuclear cells in peripheral blood, increased expression of TNF-alfa, IL-4, IL-6 and IL-13 in lung tissue, collagen fibers remodeling in lung parenchyma and increase in neutral mucus production in the airways when compared to the saline exposed animals. These changes were associated with worse lung function. The cholinergic deficiency in the animals instilled with DEP induced an increase in BAL neutrophils and lymphocytes and granulocytes in the peripheral blood, in the expression of IL-4 and TNF-alfa and in lung elastic fibers content in alveolar septa. In addition, there was an increase in acid mucus in nasal epithelium. These data suggest that, at least in part, cholinergic system interferes with pulmonary inflammation induced by DEP exposures, since animals with cholinergic deficiency exhibit some inflammatory alterations which are not observed or observed on a smaller scale in wild-type animals
9
Schallreuter, Karin U., Bhavan Chavan, and Souna M. A. Elwary. "The vesicular acetylcholine transporter is present in melanocytes and keratinocytes in the human epidermis." 2006. http://hdl.handle.net/10454/4078.
Full textAbstract:
NoThe human epidermis holds the full machinery for cholinergic signal transduction. However, the presence of the vesicular transporter (vesicular acetylcholine (ACh) transporter (VAChT)) for both choline and ACh has never been shown in this compartment. The results of this study confirm the presence of VAChT in cutaneous nerves and in both epidermal melanocytes and keratinocytes as well as in their nuclei using immunofluorescence labelling in situ and in vitro, Western blot analysis of cellular and nuclear extracts and reverse transcription-PCR. These results underline that ACh/choline transport in the non-neuronal epidermis is no different from the neuronal pathway. However, the function of VAChT in the nucleus remains to be shown.
10
Landry, St-Pierre Evelyne. "Évaluation pré-clinique du (–)-[18F]FEOBV: Profil métabolique plasmatique." Thèse, 2008. http://hdl.handle.net/1866/2696.
Full textAbstract:
Introduction. Plusieurs maladies neurodégénératives bénéficieraient de meilleures ap-proches diagnostiques, dont la maladie d’Alzheimer. Celle-ci affecte en particulier les systèmes cholinergiques du SNC, et de nombreuses études d’imagerie ont tenté d’évaluer la dégénérescence de ce système à des fins diagnostiques, à l’aide de ligands radioactifs de diverses composantes du système ACh. En définitive, la plupart de ces études ne se sont pas montrées satisfaisantes. À la recherche de meilleures approches dans ce domaine, nous avons décidé d’évaluer les possibilités offertes par le (-)-[18F]Fluoroethoxy-benzovesamicol ((-)-[18F]FEOBV), un agent émetteur de positons se liant au VAChT de façon spécifique et réversible. Avant d’en arriver à une utilisation humaine cependant, une validation animale en plusieurs étapes s’avère nécessaire, mais celle-ci nous est apparue justifiée à la lumière de résultats d’études préliminaires en TEP chez le rat, qui se sont montrées très prometteuses. Nous nous sommes donc attaqués à la caractérisation du métabolisme de cet agent. Ceci a exigé, dans un premier temps, la mise au point d’une méthode chromatographique d’analyse des métabolites sanguins et, dans un deuxième temps, l’évaluation de ces métabolites et de leur cinétique chez le rat. Ces données permettront ultérieurement, chez l’humain, de procéder à des études quantitatives en TEP. Étude #1: Une fois les paramètres chromatographiques optimisés, le TR du (–)-FEOBV fut établi à 7.92 ± 0.18 minutes. Étude #2 : Le métabolisme in vivo s’est montré très rapide et temporellement variable, mais un seul métabolite hydrophile a été identifié. La fonction d’apport au cerveau du (–)-[18F]FEOBV a pu être établie après correction pour la présence du métabolite détecté. Conclusion. Dans l’ensemble, le (–)-[18F]FEOBV semble très prometteur en tant que marqueur biologique du système cholinergique pré-synaptique.Background. Several neurodegenerative diseases would benefit from better diagnostic tools, and Alzheimer’s disease is an obvious point in case. Of interest, that disease par-ticularly affects CNS cholinergic systems. Many studies have evaluated neurodegenera-tion in that system during the course of Alzheimer’s disease, some using imaging tech-niques with radioactive ligands targeting the cholinergic system. However, most of those studies have shown rather unsatisfying results. Therefore, our team has decided to evaluate a so far never used in primates positron emitting ligand of the VAChT which reversibly binds to its target, (-)-[18F]Fluoroethoxy-benzovesamicol ((-)-[18F]FEOBV). Of course, before being able to use this ligand in a clinical setting, a multi-step animal validation needs to be performed. As initial experiments with PET imaging yielded encouraging results, assessing the metabolism of (-)-[18F]FEOBV was the next logical step. First, an HPLC methodology had to be developed to analyse blood metabolites. Then, we were able to use that methodology to analyse metabolites and their kinetics in the rat. That data will allow quantitative studies in humans with PET. Study #1: After the chromatographic parameters had been optimised, the TR of (–)-FEOBV was established at 7.92 ± 0.18 minutes. Study#2 In vivo metabolism was found to be fairly rapid and somewhat temporally variable, but a lone hydrophilic metabolite was identified. The plasmatic input function was obtained and corrected for metabolism. Conclusion. Overall, (–)-[18F]FEOBV holds promise as a potential ACh system pre-synaptic marker.
Books on the topic "Vesicular Acetylcholine Transporter"
1
Siegal, Deborah M. Brain vesicular acetylcholine transporter levels in chronic users of cocaine, methamphetamine and heroin. Ottawa: National Library of Canada, 2002.
Find full text
2
Mason, Peggy. Synthesis, Packaging, and Termination of Neurotransmitters. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780190237493.003.0012.
Full textAbstract:
The synthesis, packaging, and termination of action of neurotransmitters are detailed. There are far more varieties of peptide neurotransmitters than there are of low-molecular-weight neurotransmitters. Yet low-molecular-weight neurotransmitters are the ubiquitous workhorses of the nervous system. Acetylcholine, the catecholamines norepinephrine and dopamine, serotonin, glutamate, and GABA are examined in some depth. The vesicular transporters that carry low-molecular-weight neurotransmitters from the cytoplasm into synaptic vesicles are covered. The role of monoamines in affect and mood and the psychotropic effects of monoaminergic drugs are discussed. Principles of catecholamine synthesis are applied to understand phenylketonuria. Uptake of monoamines into neurons is discussed in the context of amphetamine, cocaine, and other drugs of abuse. Stiff-person syndrome, which results from an impairment of GABA synthesis, is introduced. The modes of action for peptide and gaseous neurotransmitters are briefly covered.
Book chapters on the topic "Vesicular Acetylcholine Transporter"
1
Khare, Parul, Aubrey R. White, Anuprao Mulakaluri, and Stanley M. Parsons. "Equilibrium Binding and Transport by Vesicular Acetylcholine Transporter." In Methods in Molecular Biology, 181–219. Totowa, NJ: Humana Press, 2010. http://dx.doi.org/10.1007/978-1-60761-700-6_10.
Full text
2
Wenzel, Barbara, Winnie Deuther-Conrad, Matthias Scheunemann, and Peter Brust. "Radioligand Development for PET Imaging of the Vesicular Acetylcholine Transporter (VAChT) in the Brain." In PET and SPECT of Neurobiological Systems, 1061–90. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-53176-8_32.
Full text
3
Tao-Cheng, J. H., and L. E. Eident. "The Vesicular Monoamine Transporter VMAT2 and Vesicular Acetylcholine Transporter VAChT Are Sorted to Separate Vesicle Populations in PC12 Cells." In Advances in Pharmacology, 250–53. Elsevier, 1997. http://dx.doi.org/10.1016/s1054-3589(08)60740-1.
Full text
4
Varoqui, H., F. M. Meunier, F. A. Meunier, J. Molgo, S. Berrardxy, R. Cervini, J. Mallet, M. Israël, and M. F. Diebler. "Chapter 6 Expression of the vesicular acetylcholine transporter in mammalian cells." In Cholinergic Mechanisms: from Molecular Biology to Clinical Significance, 83–95. Elsevier, 1996. http://dx.doi.org/10.1016/s0079-6123(08)62090-7.
Full text
5
Schütz, Burkhard, Eberhard Weihe, and Lee Eiden. "Targeting of the vesicular acetylcholine transporter to cholinergic subdivisions in transgenic mice." In Cholinergic Mechanisms, 691–93. CRC Press, 2004. http://dx.doi.org/10.3109/9780203493878-132.
Full text
6
Parsons, Stanley M., Gary A. Rogers, and Lawrence M. Gracz. "[7] Photoaffinity labeling of vesicular acetylcholine transporter from electric organ of Torpedo." In Methods in Enzymology, 99–116. Elsevier, 1998. http://dx.doi.org/10.1016/s0076-6879(98)96009-8.
Full text
7
Varoqui, Helene, and Jeffrey D. Erickson. "[6] Functional identification of vesicular monoamine and acetylcholine transporters." In Methods in Enzymology, 84–99. Elsevier, 1998. http://dx.doi.org/10.1016/s0076-6879(98)96008-6.
Full text
8
Diebler, M. F., Y. Morot Gaudry-Talarmain, J. C. Lancelot, M. Robba, J. L. Morgat, and M. Israel. "Comparison of the Effects of Vesamicol and of Cetiedil Analogues on Acetylcholine Release and Vesicular Acetylcholine Transport." In Presynaptic Receptors and Neuronal Transporters, 177–78. Elsevier, 1991. http://dx.doi.org/10.1016/b978-0-08-041165-1.50065-x.
Full text
9
Zhang, Lu, Mark Prendergast, and Jerry Buccafusco. "Estimation of the mRNAs Encoding the Cholinergic Muscarinic Receptor and Acetylcholine Vesicular Transport Proteins Involved in Central Cardiovascular Regulation." In Molecular Regulation of Arousal States. CRC Press, 1997. http://dx.doi.org/10.1201/9780849333613.ch2.
Full text
10
Zhang, Lu, Mark Prendergast, and Jerry Buccafusco. "Estimation of the mRNAs Encoding the Cholinergic Muscarinic Receptor and Acetylcholine Vesicular Transport Proteins Involved in Central Cardiovascular Regulation." In Molecular Regulation of Arousal States. CRC Press, 1997. http://dx.doi.org/10.1201/9781420048940.ch2.
Full textConference papers on the topic "Vesicular Acetylcholine Transporter"
1
Thayabaran, M., and S. G. Yasawardene. "Immunohistochemical localization of Vesicular Acetylcholine Transporters and Choline Acetyl Transferase activity in murine and human immune tissues." In Annual International Conference on Microscopic and Macroscopic Anatomy. Global Science & Technology Forum (GSTF), 2014. http://dx.doi.org/10.5176/2382-6096_cmma14.18.
Full text